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Low potassium diets are recommended to reduce serum potassium and prevent complications
of chronic kidney disease (CKD); but evidence underpinning this recommendation has not
been systematically reviewed and synthesised. We conducted a systematic review comparing
change in serum potassium, CKD progression and mortality between those on a low versus
unrestricted potassium diet.
Methods
We searched Medline, AMED, PsychInfo, CINALH, Cochrane Central Register of
Controlled Trials and Clinicaltrials.org from inception to 3 April 2018. We included 
randomised and observational studies that compared these outcomes in CKD adults who ate a
restricted versus unrestricted amount of dietary potassium. We pooled mean change in serum
potassium and adjusted hazard ratios of disease progression and mortality using random
effects meta-analyses.
Results
We identified 5563 articles of which seven studies (3489 participants) met our inclusion
criteria. We found very low quality evidence that restricted (1295mg/d) versus unrestricted 
(1570mg/d) dietary potassium lowered serum potassium by -0.22mEq/L (95% CI: [-0.33, ­
0.10] I²=0%). Lower (1725mg/d) versus higher (4558mg/d) dietary potassium was not
significantly associated with disease progression (HR; 1.14, 95% CI: [0.77, 1.70] I²= 57%). 
Lower (1670mg/d), compared with higher (4414mg/d) dietary potassium intake was
















     












Very low quality evidence supports consensus that dietary potassium restriction reduces
serum potassium in normokalaemia, and is associated with a reduced risk of death in those
with CKD. High quality randomised controlled trials are needed.
Introduction
Serum potassium (Sk) > 5.5 mEq/L usually denotes hyperkalemia1 although outlying
thresholds of >6.0mEq/L or >7.0mEq/L exist. Hyperkalaemia, a common symptom of
chronic kidney disease (CKD), affects 14 to 20% of the 30 million people worldwide with 
CKD;2 it can lower resting cardiac membrane potential and increase cardiac conduction
velocity, thereby increasing cardiac arrest risk.3Evidence suggests hyperkalaemia (≥ 5.5 and
<6.0 mg/dl) in CKD is associated with an increase in one-day mortality risk (OR; 5.40 [95%
CI: 4.72, 6.18]) ,4 increased mortality risk after 15 years (RR 2.15, 95% CI [1.17-3.96])5 and 
for every 0.1mEq/L rise in Sk ≥6.0 mEq/l, mortality risk may increase by 28%, although this
association was not statistically significant to 1.28 (95%CI: [0.99-1.64]).6 
Dietary potassium restriction assumes dietary potassium directly affects Sk level and is
recommended around the world to treat hyperkalaemia in CKD.7 However several
inconsistencies exist.
Although laboratory studies on renal insufficient animals’ demonstrate cardiac arrest with 
hyperkalemia from high potassium exposure 8 and dietary potassium restriction reduces
serum potassium in hyperkalemia,9 randomised controlled trial (RCT) evidence showing
dietary potassium restriction causes a reduction in Sk appears limited. Case studies suggest
that hyperkalemia (Sk >7.3mEq) is unrelated to a modified dietary potassium intake (58 
mEq/day); but due to increased renal Sk secretion,10 whereas cross-sectional studies suggest a
positive association between dietary potassium and Sk.11 As a result of this, clinical 
recommendations for dietary potassium restriction CKD are often opinion based; and
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inconsistent across countries. For example, actual body weight (1mEq/K+/kg/ ABW),12 ideal
body weight (1mEq/K+/kg/IBW),13 and a set range of 2000-2500mg/day (50-65mmol/day)
are all used to calculate individual dietary potassium.14 Hyperkalaemia threshold levels for
dietary potassium management CKD stages also differ, for example, stage 4 interventions
vary; from Sk >5.5mEq/L in the UK15 to 6.0mEq/L in Australia.16 Such inconsistencies raise 
the question as to how effective and necessary dietary potassium restriction in CKD actually
is? This is particularly important, as a qualitative synthesis of evidence shows that dietary
potassium restriction is detrimental to quality of life,17 is difficult to follow, even when 
supported by renal dietitians,18 and is consistently associated with poor general well-being
and psychological stress.19-22 
The objectives of this review were to assess the effect of dietary potassium restriction on
serum potassium, and the association of potassium intake with CKD progression and 
mortality in CKD
Methods
Search strategy and selection criteria
This review was conducted and reported in accordance with published guidelines 23,24 using a
pre-specified protocol and PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analysis) guidelines.23 The search strategy (available in the supplementary table S1)
was created by two experienced review authors (AM, DL). We searched Medline, CINAHL,
AMED, PsychInfo, Cochrane Database of Systematic Reviews, Cochrane Central Register of
Controlled Trials and Clinicaltrials.org databases since inception to 4 April 2018. Medical
subject headings (MeSH) terms, and keywords including: (Food or Diet or Nutrition or
Nutritional Therapy) and (Potassium or Hyperkalemia or Hypokalemia) and (Renal or





















    
   
   
 
were adapted for each database. The search was limited by study type to include reviews,
clinical trials and cohort studies. No language limitation was applied. Clinical trial databases
were searched for unpublished literature. Conference abstracts were included and where there 
was no full publication, authors were contacted to provide data. Conference abstracts were
rejected if we could not obtain the full text article from authors. We manually searched
reference lists of relevant articles and clinical guidelines identified in the previous step and
conducted a forward citation search of narrative reviews on dietary potassium in CKD. Two 
investigators reviewed each article to confirm eligibility using a study protocol. A third
investigator was consulted where there was disagreement so consensus could be achieved.
We included studies on adults with any stage of CKD including dialysis or transplantation. 
We excluded studies where there was no intentional difference between dietary potassium
intake or urinary potassium (Uk) level in the intervention and control group, or between 
exposure conditions. Eligible interventions/exposures provided potassium from food, oral
nutritional supplements, enteral nutrition, or any combination of these. RCTs, non­
randomised clinical trials and cohort study designs were included. We excluded adults with 
acute kidney injury, animal studies, laboratory studies, qualitative studies, and case studies. 
The outcomes were serum potassium, disease progression and all-cause mortality. We 
excluded studies that did not report these outcomes.
Data Extraction
Two investigators extracted the data independently using a data extraction form
(supplementary form S1). The results of the data abstraction were compared by a third 
investigator after the review of the articles was complete. The investigators were not blinded
to the authors and the institution of the studies undergoing review. Data extracted from
intervention studies included: study type, population characteristics, description of
5
  





   
 
   
  
   














intervention and control conditions, number of patients included, baseline and follow-up of
outcomes of interest. Data was only used once if several studies published data from the same
participants. From observational studies we collected data on cohort characteristics, time to
follow-up, dietary or urinary potassium, details of adjusted confounders, and outcomes, 
disease progression and mortality events in the lowest and highest dietary potassium exposure
groups. For some studies, the reference category for the log hazard ratio inference was an
intermediate category, rather than the lowest or the highest category. In such cases, the 
standard error (SE) for the log hazard ratio between the lowest and highest exposure groups
was approximated as the square root of the sum of the squares of the two SEs for the log
hazard ratios comparing the reference category to the lowest and highest groups. This
assumes log hazard ratio estimates are independent.
We requested any relevant missing information from original study authors. Risk of bias and 
quality of the included studies were assessed by using the RCT /Non-RCT Cochrane review
risk of bias criteria.25 For RCTs the risk of bias identified as high, low or unclear was
assessed for the method of sequence generation, allocation concealment, blinding, selective
reporting, loss to follow-up, and completeness of reporting outcome data. The ROBINS-I tool
was used to assess risk of bias in observational studies as per published guidelines.25 The 
certainty of the overall evidence related to each outcome was assessed by two investigators
using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach.26 Certainty was assessed against the following domains: risk of bias, inconsistency, 













   













We compared dietary potassium restriction to no dietary potassium restriction or low to high 
dietary potassium intakes or urinary potassium. Where a study had more than one
intervention group or several levels of exposure we compared the lowest or most restricted 
potassium intake with the least restricted or highest intake. We estimated total dietary
potassium intake assuming a 77% excretion rate of total dietary potassium intake per day. 27
For continuous outcomes (e.g. Sk change) we pooled the mean differences. For time to event
outcomes (e.g. mortality) we pooled the log hazard ratios from models which adjusted for
confounders. We used random effect models in all meta-analyses because of high
heterogeneity between trial interventions meaning that exactly the same effect was not
expected from each. One investigator input the data into Review Manager Software.28 A 
second investigator checked the data entry for accuracy. We quantified heterogeneity using
the I² metric and used the chi-squared to test if the heterogeneity was statistically significant.
I² >75% alongside a statistically significant heterogeneity was considered to indicate 
substantial heterogeneity.25 A priori sub-analysis grouping similar interventions, study type, 
population (dialysed or not) and time to follow-up were considered. Sensitivity analysis to 
examine the effect of removing studies at high risk of bias from the analysis was also 
considered. Results were taken as statistically significant at p<0.05.
Results
Our search yielded 5,563 publications (figure 1) that included key words. Of these, 5,558 
studies were identified by the electronic search strategy and five from the reference lists of
narrative reviews. After removing duplicate publications, irrelevant publications and studies
that did not meet the inclusion criteria, 580 articles were examined in further detail, of which 










    
 
   








   
  







Figure 1: Study selection
Two RCTs 29,30 and five observational studies31-35 were included, with a total of 3489 adults
with CKD stages 3, stage 4, and stage 5 on heamodialysis, and post-transplant ≥ one year. At
the first visit from enrolment Sk were all within normal biochemical range i.e. no studies
reported baseline hyperkalaemia. One RCT in CKD stage 3 prescribed an intervention of 1 
mEq/kg/d of potassium over 24 months versus no dietary restriction in the control group, 
unless Sk>6mEq/L, then a restriction of 1mEq/L/kg/ IBW/d was prescribed.29 The other
RCT exposed participants with end-stage renal failure (ESRF) to highly controlled amounts
of potassium, from the content of a renal specific oral nutritional supplements (250.5mg/
220ml), which were used as a sole source of nutrition over three weeks and compared to 
generic oral nutritional supplements (296mg/ 220ml).30 There was no intentional overlap 
between the amount of dietary potassium in the intervention and control conditions across
these trials.
Norri et al.31 observational cohort study reported four quartiles consuming potassium at 879
±161 mg/d, 1342 ±109 mg/d, 1852 ±217 mg/d and3440 ±969 mg/d. Eisenga et al.32 reported 
three urinary potassium quartiles over 3.1 years: 48.2±11.0 mEq/L/24h, 70.6± 7.8mEq/l/24h 
and 98.9± 16.7 mEq/L; He et al.33 reported four quartiles over 5 years 30.5±6.6 mEq/L/24h, 
45.9±3.7mEq/L/24h, 59.0±4.3mEq/L/24h and86.1±24.4mEq/L/24h; Leonberg-Yoo et al.34
reported four baseline urinary potassium quartiles over 6.1 median follow-up years: 1.41±
0.27g/d, 2.01± 0.14g/d, 2.54± 0.20g/d and 3.60 ±0.66g/d; and Nagata et al.35 compared
<1.5g/d, 2.0-2.5g/d and 2.5-3.0g/d over 5.47 mean follow-up years. Further characteristics of
included studies, with quartiles used in the meta-analyses and the estimated total dietary
intake from Uk are listed in table 1.







   
  
 










    





There was low risk of bias for all key domains in one RCT29 and unclear risk of bias was
present across most domains in the other RCT30. Confounding bias and selection bias from
study datasets were present in this RCT30. Across the four cohort studies reporting Uk 
outcome, there was serious risk of bias due to confounding, selection of participants, missing
data and measurement of outcomes. There was moderate risk of bias across selection of
reported results. There was severe to moderate risk of bias across one cohort study reporting
long term mortality data.
Sk was stated as a primary outcome in both RCTs.29,30 In one RCT,29 a prescribed reduction 
of 1mmol/kg IBW/d dietary potassium resulted in a greater reduction from baseline at 24 
month follow-up (-0.2 ±0.64mEq/L) when compared to an unrestricted diet (­
0.05±0.64mEq/L). Within the intervention group, however, 47.6% of participants on a dietary
restriction received a mean 19.8±7.8g/d sodium polystyrene sulfonate to maintain Sk
≤4.5mEQ/L over a mean time of 19.5±5.4 months. The second RCT was of short duration 
and at final follow up (22 days from baseline visit) the mean Sk was lower in the dietary
restricted group taking lower potassium oral nutritional supplements (251mg/220ml) (total
potassium intake on days 12-21was1128-1279mg/d) than the unrestricted group (total
potassium intake on days 12-21 was 1390-1567mg/d) on standard oral nutritional
supplements (296mg/220ml).30 The intervention group showed a greater mean reduction from
baseline by -0.5 mEq/L than the control group (-0.3mEq/L). 
Pooling these results in a meta-analysis showed that at the final follow-up, the mean Sk in the
restricted (1295 mg/d, see table S2 for estimation) was lower than the mean Sk in the non­
9
  






























restricted (1570 mg/d) group (mean difference -0.22mEq/L, [95%CI:-0.33, -0.10], P=0.0002, 
I2=0%).
Figure 2: Change in serum potassium between baseline and follow- up in those
restricting dietary potassium versus those eating an unrestricted diet.
Adults consuming lower intakes (1725mg/d) were 14% more likely to experience a decline in 
kidney function (as measured by minimum reduction of 5% in eGFR) (HR 1.14; 95% CI:
0.77-1.70, P=0.5); compared to those with higher intakes (4558mg/d) at follow-up (figure 3);
although this was not a statistically significant result.
Figure 3: Meta-analysis of adjusted hazard ratios of CKD progression comparing 
lowest to highest urinary potassium between 3 to 5 year follow-up
Participants consuming low levels of dietary potassium (1670mg/d) had 40% lower risk of
death (HR 0.60; 95% CI: 0.4, 0.89, P=0.01) compared to those who consumed higher
amounts of dietary potassium (4414mg/d) at follow-up between three to five years (figure 4).
Figure 4: Meta-analysis of adjusted hazard ratios for risk of mortality comparing lowest
to highest urinary and dietary potassium between 3 to 5 years
Qualities of Evidence (GRADE) for three outcomes, analysed change in serum potassium, 
morbidity and mortality were analysed (table 2). Very low quality evidence from the RCTs

















    
  
 






   
 
   
   
  
potassium. Observational studies provided very low quality evidence that a lower intake of
dietary potassium compared to a higher intake of dietary potassium is associated with a 
reduced mortality risk, but not with reduced disease progression. No details on the baseline
confounding and selection of participants were reported in the observational studies to make
an informed decision; therefore this evidence was downgraded by one.
Table 2: GRADE quality of evidence summary
Discussion
Dietary potassium restriction may reduce baseline normokalaemic serum potassium levels, in
those with CKD, when compared to a higher potassium intake. However, the effect we saw
was driven by one RCT where dietary potassium was strictly controlled (33.2 ±3.37 mEq)
and possibly unattainable eating normal foods as participants received a manufactured liquid 
diet as a sole source of nutrition. Nonetheless, the control diet was also a relatively low
potassium intake (40.2±3.85 mEq) and was considered a low intake in the cohort studies, and 
within clinical practice. Therefore, the reduction in serum potassium may have been greater
when compared with a truly unrestricted diet.
It is unclear whether restricting dietary potassium is associated with a reduced risk of CKD
progression but our results suggest that they may be associated with a reduction in all-cause 
mortality in CKD. However these results are based on very low quality evidence and there is
a high risk of uncertainty around them. Nonetheless, this is the first pooling of the evidence to 
date and suggests that the body of available evidence does support the practice of dietary
potassium restriction in those with normokalemia in CKD. However, there are still no studies




























   
Our meta-analyses results are in keeping with Kidney Disease Improving Global Outcomes
clinical guideline that potassium supplementation cannot be recommended in any stage of
CKD (non-dialysis) to reduce blood pressure, 36 due to the lack of definitive studies 37.
We acknowledge though, that our meta-analysis is based on very low quality evidence. Our
meta- analyses also offers support to current opinion that dietary potassium intakes should be
limited to 2000-2500mg/d (50-65mmol/d) in CKD stage 5 on maintenance haemodialysis, to 
help maintain normokalemia.14 
From the meta-analysis of these observational studies, we found little evidence to support the
guidelines for reducing potassium intake in CKD stages 3-4 to prevent progression. However, 
we did find evidence to show dietary restriction may be associated with a reduction in all-
cause mortality in those with CKD stages 3-5. In view of this we would recommend dietary
potassium restriction continues to be practiced in these stages, however, this is informed by
very low quality evidence. Furthermore, pathophysiological evidence that reducing potassium
intake reduces the polarising effect of potassium on cardiac cells3 remains controversial.
Without further investigation the real effect of dietary restriction on serum potassium and all-
cause mortality remains unknown
We note that our results were limited by the inclusion of a small number of studies each of
which had their own limitations. Additionally pooling data resulted in heterogeneity; however
this difference was not statistically significant as per our defined criteria (I²>75%).
Measurement of dietary potassium is problematic due to the known inaccuracies of self-

























were careful to remove studies where there was no actual difference between exposures to
dietary potassium.
We also ensured that the urinary potassium quartiles did not overlap which offered some
reassurance that dietary exposure was different, between the lowest and highest group.
Taking urinary potassium as a surrogate marker of dietary potassium intake has limitations
too; Uk may not be an exact match for dietary intake, and it may not reflect total body
potassium stores.38 A fractional absorption rate of 77% in healthy adults has been reported,27
but the rate in CKD is less well known, although one included observational study reported 
Uk and dietary potassium intake correlated well in CKD (r=0.44, p<0.001).32 
Nonetheless, these limitations are characteristic of all such studies and not a unique limitation
to our study. However, publication bias was not assessed using funnel plot asymmetry due to
the small number of included studies. We therefore assumed bias was present when 
considering the overall quality of evidence.
While we suggest, based on current available evidence, it is prudent to continue to restrict
dietary potassium in individuals with CKD, there are important questions that remain 
unanswered and a definitive trial is needed. Such a trial would include a clear difference 
between dietary potassium intake in the control and intervention groups. Dietary advice 
would need to be achievable in ‘free-eating’ individuals and adherence checked by also 
measuring urinary potassium. As well as the need for this in those with normokalaemia, 






   
















   
    
     
  
   
   
  
Dietary potassium restriction does seem a prudent approach in normokalaemic chronic
kidney disease to keep potassium levels low and reduce mortality risk, but this is based on 
very low quality evidence. With no quality of life quantitative data around following dietary
potassium restrictions to inform practice, it would seem sensible to check for any reported 
adverse impact of a low potassium diet on a person’s lifestyle, and discuss alternative
approaches to achieving the desired level of dietary potassium.
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Study type Length of study Patients on a reduced
potassium intake (outcome: 
(Sk) serum potassium, (Uk)
urinary potassium)
Amount of dietary 
potassium consumed per
day on a reduced intake
(estimated from urinary
potassium * or actual
intake)
Patients exposed to higher 
potassium intakes
(outcome: (Sk) serum potassium,
(Uk) urinary potassium)
Amount of dietary potassium






Adults with CKD stage 3













Adults with CKD stage 5













Adults with CKD stage 3
who had received a renal
transplant >1 year





37 months follow-up n=235 (Uk)
Urinary potassium excretion 
48.5±11.0mEq/24hour
2453.1±553.8mg/24hour n=235 (Uk)
urinary potassium excretion 
98.9±16.7mmol/24hour
5007.6±842.4mg/24hour






















































60 month follow-up n= 56 (Sk)
dietary intake 879±161 
mg/24hour
879±161 mg/24hour n=56 (Sk)
dietary intake 3,440±969 mg/24hour
3440±969 mg/24hour
Table 1 : Characteristics of included studies
Notes
* Assuming 77% of total dietary potassium intake is excreted (Holbrook et al.1984)
 
** The combined mean and SD from day 8 to 21 were calculated. Both EN-9528 and EN-9529 were pooled as lowest potassium intakes. Pooled SD were calculated used Cohen (1988) method
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Table 2: GRADE summary of evidence
Certainty assessment № of patients Effect
Certainty
NNT
Numbers needed to treat№ of










Change in serum potassium
2 randomised 
trials
very serious a not serious not serious not serious publication bias strongly
suspected b 






CKD progression (assessed with urinary potassium)
4 observational
studies
serious c serious d very serious e serious f publication bias strongly
suspected g 







VERY LOW NNT 14
Mortality (assessed with urinary potassium and dietary potassium)
4 observational
studies
serious c serious h very serious e serious f publication bias strongly
suspected i 





fewer to 17 
fewer)
⨁◯◯◯
VERY LOW NNT 167
CI: Confidence interval; MD: Mean difference; HR: Hazard Ratio
Explanations
a. Cockram et al. 1998 influenced the overall effect but did not report how participants were selected, allocated to groups. There was an intentional difference in dietary exposure, however, both groups could have been exposed to the same amount of dietary potassium. Blinding of
participants may have been possible as the cartons of nutritional supplements may have been generic, but it is not known. Blinding of outcome assessment was unknown. Arnold et al. (2017) >40% of the intervention group received potassium binding medication to achieve the target
serum potassium level.
b. Both studies have reported that a lower potassium intake results in a greater change from baseline in the intervention groups.
c. All studies had serious risk of bias across 5 domains (bias due to confounding, bias in selection of participants, bias due to deviations from intended interventions, bias due to missing data/ lost to follow-up and bias in measurement of outcomes).
d.Heterogeneity substantial as per GRADE (I²= 57%)
e. Urinary potassium used as a surrogate of dietary potassium intake
f. Large confidence intervals around effect size
g. Publication biased not assessed - bias assumed.
h. Substantial heterogeneity as per GRADE (I²= 56%)



















































Figure 1 Study selection
Records identified through database 
searching
(n =5557)
Trial data base searching (n=1)
Additional records identified through
hand searching of references and
forward citation searches
(n =5)





Full-text articles assessed for
eligibility
(n = 580)








Full-text articles excluded, with
reasons (n=573):
Not clinical trial or cohort n=433
No intervention or exposure to
dietary potassium n=68
No dietary potassium comparator
n =28
Population inappropriate n=31
No planned difference in mean
dietary potassium intake between
intervention and comparison 
groups n=12
























Figure 2: Change in serum potassium between baseline and follow- up in those
restricting dietary potassium versus those eating an unrestricted diet.
Figure 3: Meta-analysis of adjusted hazard ratios of CKD progression comparing 
lowest to highest urinary potassium between 3 to 5 year follow-up
Note: Nagata et al. contained deaths (n=2) within the morbidity data.
Figure 4: Meta-analysis of adjusted hazard ratios for risk of mortality comparing lowest










       










   
 




     
     
       
     
         





   
 
      
     
     
       
     
       
     
  
 
   
 
      
     
     
       
     
       
    
  
 
   
 
      
     
     
       
     
       
    
  
 
   
 
      
     
     
Table S1
Table S1 Electronic Search Strategy
Search
Interface - EBSCOhost Research
Databases
S13
(S1 OR S2 OR S3 OR S4 OR S5 OR S6)







Search Screen - Advanced
Search
Database - CINAHL Complete;





(DE "KIDNEY") OR (DE "RENAL
DIALYSIS") OR (DE "KIDNEY FAILURE








Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;





       










   
 




     
     
       
     
       
     
  
 
   
 
      
     
     
       
     
       
    
  
 
   
 
      
     
     
       
     
       
    
  
 
   
 
      
     
     
       
     
       
    
  
 
   
 
      
     
     
  
    
 
   
 
   
 
    
     











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;









Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;
34,068
 






      
        
     
       





   
 
      
      
      
     
       
     
       
    
  
 
   
 
      
     
     
search
terms




(MH "Diet+") OR (MH "Restricted
Diet+") OR (MH "Renal Diet") OR
(MH "Diet Therapy+") OR (MH "Diet
Records") OR (MH "Nutrition
Therapy+") OR (MH “Nutritional
Requirements”) OR (MH "Nutritional
Support") OR (MH "Enteral









Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;











Interface - EBSCOhost Research
Databases
Search Screen - Advanced
Search
Database - CINAHL Complete;


























































     
 
     
 
 
     
 




     
 
     
 
 
     
 
     
 
 




          
Table S2






























consumed per day on











Weighted mean amount of dietary
potassium consumed per day
Weighted mean amount of dietary
potassium consumed per day -
morbidity
Weighted mean amount of
dietary potassium consumed per
day - mortality












7.0% 15.5% 2453.1±553.8mg/24hr 5007.6±842.4mg/24
hr
171.7 mg/24hr 350.5 mg/24hr 380.2mg/24hr 776.2 mg/24hr
He et al
(2016)
45.2% 36.1% 1544.4±179.4mg/24hr 4360.2±1232.4mg/2
4hr




40.6% 32.4% 1825.2±347.1mg/24hr 4672.2±854.1mg/24
hr





114.8 mg/24hr 340.0 mg/24hr
Noori et
al (2010)












         
 
  
         


































































Design (including intervention type, ethical approval, randomisation etc.)
Study duration
Participants (setting, recruitment, age, sex, race CKD stage, co-morbidities)
Country
Study groups
Please include description of intervention, number of groups receiving intervention, duration of
intervention, delivery and timing of intervention and by whom, compliance, drop-outs, co-
interventions e.g. K+ binding medication, laxatives, insulin etc.
Intervention group








































Urinary potassium intervention group
Comparison group
Dietary potassium comparison group




     
  
Outcomes
Please include outcome name, time points measured and reported, units, validated collection






































Was there a true difference between exposure to dietary potassium between the intervention and
comparison groups?
Please provide evidence, e.g. show calculations if undertaken to inform your decision, confidence
intervals with an explanation.
Dietary potassium
True difference in intervention






























True difference in intervention










































Inclusion caveats, if applicable. If none, state NONE.
Peer reviewer’s decision
Include/ exclude (please circle)
Rationale
